InspireMD, Inc. (NSPR): Entry into a Material Definitive Agreement

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 InspireMD Announces Pricing of $37.5 Million Public Offering Miami, FL -- November 13, 2026 — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing

Event · Offering · priced
Instrument
common stock
Shares
7,342,308 shares
Gross proceeds
$37.5 Million

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 16, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$NSPR
Bearish
high confidence
Mentioned
$NSPR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NSPRBearishMed
01

Why it matters

The offering adds $37.5 M of capital but introduces up to 15% additional shares, likely diluting earnings per share and prompting short‑term price weakness.

02

Market read

Primary disclosure of a new capital raise for a micro‑cap biotech; relevant for short‑term traders and long‑term investors assessing dilution versus growth funding.

03

What to watch

Recall risk for the CGuard Prime system and existing cash burn may offset benefits of the raise.

Relevance 6/10Novelty 7/10Timing: today

Background

InspireMD (Nasdaq: NSPR) develops carotid stent systems and filed an 8‑K to disclose the pricing of its latest equity offering.

Company-level read

Ticker impact

$NSPRBearishHigh confidence
Context

InspireMD announced pricing of a $37.5 million public offering of common stock, pre‑funded warrants and common warrants.

Expected impact

downward pressure as market prices in dilution

Evidence & confidence

New equity issuance of ~15% over‑allotment option signals supply increase; investors typically react with short‑term price decline.

Market effects

Medical‑device and biotech stocks may see heightened scrutiny on dilution risk.

US listed biotech sector could experience modest sell‑off pressure.

Limited to investors tracking small‑cap medical‑device issuers.

Counterpoint

The proceeds could fund R&D and accelerate product rollout, supporting a longer‑term upside.

Key entities

  • InspireMD, Inc.

    Medical‑device firm issuing new equity.

  • Lake Street Capital Markets

    Sole book runner for the offering.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRHighAI 8/10

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR